Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt Sells 5,000 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $122.25, for a total value of $611,250.00. Following the completion of the sale, the chief financial officer owned 42,181 shares in the company, valued at $5,156,627.25. The trade was a 10.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Bjerkholt also recently made the following trade(s):

• On Monday, June 8th, Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.82, for a total transaction of $469,100.00.

Mirum Pharmaceuticals Stock Up 0.2%

Mirum Pharmaceuticals stock opened at $128.57 on Thursday. The stock has a fifty day simple moving average of $105.26 and a two-hundred day simple moving average of $97.20. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. The firm has a market cap of $7.84 billion, a price-to-earnings ratio of -9.45 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a 12 month low of $50.25 and a 12 month high of $129.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The company had revenue of $159.88 million for the quarter, compared to analysts’ expectations of $148.21 million. During the same quarter in the prior year, the firm posted ($0.30) earnings per share. Mirum Pharmaceuticals’s quarterly revenue was up 43.3% on a year-over-year basis. Equities analysts predict that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Morgan Stanley lifted their target price on Mirum Pharmaceuticals from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Thursday, June 11th. Evercore reiterated an “outperform” rating and issued a $138.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Citizens Jmp upped their price objective on shares of Mirum Pharmaceuticals from $140.00 to $146.00 and gave the stock a “market outperform” rating in a research note on Monday, June 15th. JPMorgan Chase & Co. boosted their target price on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Finally, TD Cowen increased their price objective on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $143.40.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in MIRM. Glenmede Trust Co. NA grew its holdings in shares of Mirum Pharmaceuticals by 66.9% during the 1st quarter. Glenmede Trust Co. NA now owns 5,532 shares of the company’s stock worth $511,000 after purchasing an additional 2,217 shares during the period. Janus Henderson Group PLC boosted its holdings in Mirum Pharmaceuticals by 14.5% in the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after purchasing an additional 880,505 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in Mirum Pharmaceuticals during the 1st quarter worth $573,000. California State Teachers Retirement System boosted its position in shares of Mirum Pharmaceuticals by 22.1% in the 1st quarter. California State Teachers Retirement System now owns 44,476 shares of the company’s stock valued at $4,109,000 after purchasing an additional 8,065 shares during the period. Finally, Rock Springs Capital Management LP boosted its holdings in shares of Mirum Pharmaceuticals by 6.4% in the first quarter. Rock Springs Capital Management LP now owns 811,294 shares of the company’s stock valued at $74,947,000 after acquiring an additional 49,000 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.